115 related articles for article (PubMed ID: 25085753)
1. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.
Jerjees DA; Alabdullah M; Alkaabi M; Abduljabbar R; Muftah A; Nolan C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Aug; 147(1):25-37. PubMed ID: 25085753
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
5. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen.
Bergqvist J; Elmberger G; Ohd J; Linderholm B; Bjohle J; Hellborg H; Nordgren H; Borg AL; Skoog L; Bergh J
Eur J Cancer; 2006 May; 42(8):1104-12. PubMed ID: 16603346
[TBL] [Abstract][Full Text] [Related]
6. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
[TBL] [Abstract][Full Text] [Related]
7. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
8. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
Manikhas AG; Skvortsov VA; Manikhas GM; Raskin GA; Oganesian AS; Shemerovskiĭ AK
Vopr Onkol; 2011; 57(5):641-4. PubMed ID: 22238936
[No Abstract] [Full Text] [Related]
9. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Oncol Rep; 2003; 10(1):141-4. PubMed ID: 12469160
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
[TBL] [Abstract][Full Text] [Related]
12. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
[TBL] [Abstract][Full Text] [Related]
14. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
Grabau DA; Bendahl PO; Rydén L; Stål O; Fernö M;
Acta Oncol; 2013 Nov; 52(8):1657-66. PubMed ID: 23343224
[TBL] [Abstract][Full Text] [Related]
16. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.
Svensson S; Jirström K; Rydén L; Roos G; Emdin S; Ostrowski MC; Landberg G
Oncogene; 2005 Jun; 24(27):4370-9. PubMed ID: 15806151
[TBL] [Abstract][Full Text] [Related]
17. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.
Ahmad DA; Negm OH; Alabdullah ML; Mirza S; Hamed MR; Band V; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Oct; 159(3):457-67. PubMed ID: 27592113
[TBL] [Abstract][Full Text] [Related]
20. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]